The Health Innovation Network has produced a summary of findings showing the impact of its lipid management and familial hypercholesterolaemia (FH) national spread programme.
The programme, which ran from October 2020 to March 2023, aimed to tackle cardiovascular disease (CVD), which is one of the areas of improvement identified in the NHS Long Term Plan and a priority for reducing health inequalities in NHS England’s Core20PLUS5. Cardiovascular disease is the cause of around 1.18 million hospital admissions each year, with annual costs of approximately £19bn in the UK.
The programme increased the uptake of lipid lowering therapies, the identification and management of people with FH, and enabled adoption of endorsed treatment pathways.
With a focus on primary care, it achieved this through engagement and education events, supporting clinicians to identify those at risk, so they could in turn support patients to lower their lipids. It was anticipated that these interventions would in turn lead to a fall in the number of major cardiovascular events, such as heart attack or stroke.
The summary includes data from an independent evaluation by Unity Insights, and other sources such as CVDPREVENT and UCLPartners ‘Size of the Prize’ infographics.
Achievements during the programme include:
- The total proportion of people with known CVD treated to NICE-recommended thresholds increased from 23.7% to 27.8% (March 2021 – March 2023).
- The improvement in lipid management achieved across England is estimated to have prevented over 9,000 heart attacks and strokes.
- The identification of genetically confirmed familial hypercholesterolaemia increased from 9.6% to 13.8%.
Prof Julia Newton, Medical Director, Health Innovation North East and North Cumbria, and Executive Lead for the National Lipid Management and Identification of Familial Hypercholesterolaemia Programme, said:
‘As an example of one of the Health Innovation Network led national spread programmes, the lipids and FH programme was able to demonstrate the concept that a whole pathway improvement programme at a national level can be successfully implemented, and have a positive impact on the management of cardiovascular disease supporting delivery of the ambitions outlined in the NHS Long Term Plan.’
Lesley Bull, a South London GP and our 1000th delegate chats to Lois-Hooper Ainsworth, Programme Coordinator on the National Polypharmacy Programme, about why she registered for the Health Innovation Network Polypharmacy Action Learning Set, what she got out of it and why other GPs should attend. Lesley Bull So, Lesley, could you tell [...]
Jo Barosa is Account Director at Qbtech UK. Qbtech is a market leading provider of innovative objective tests for assessing and treating ADHD, changing the landscape of ADHD care. Driven by its mission to improve the lives of people with ADHD, Qbtech supports by providing digital and clinical solutions to improve clinical decision making, service [...]
Dr Cheryl Crocker, interim Chief Operating Officer at the Health Innovation Network, explains the vital role innovation plays to not only reduce waiting lists and improve access to care, but to decrease system pressure by improving people’s health and keeping them well for longer. The new Government has rightly declared its focus on moving the [...]
